The invention provides a method of screening for a compound that modulates RIZ histone methyltransferase (HMT) activity, by contacting a RIZ or RIZ fragment having HMT activity with one or more candidate compounds, and determining histone methyltransferase activity of the contacted RIZ or RIZ fragment. Also provided is a method of screening for a compound that modulates progesterone receptor (PR) activity, by providing a RIZ1 modulatory compound, and determining the ability of the RIZ1 modulatory compound to modulate PR activity. Further provided is a method of identifying an individual with an estrogen receptor positive (ER+) tumor having a reduced likelihood of responding to endocrine therapy. The method involves determining the RIZ1 status of the tumor, wherein an abnormal RIZ1 status identifies the individual as an individual with a reduced likelihood of responding to endocrine therapy.
本发明提供了一种筛选调节RIZ组蛋白甲基转移酶(H
MT)活性的化合物的方法,该方法通过将具有H
MT活性的RIZ或RIZ片段与一种或多种候选化合物接触,并测定接触的RIZ或RIZ片段的组蛋白甲基转移酶活性。还提供了一种筛选调节
孕酮受体(PR)活性的化合物的方法,其方法是提供一种 RIZ1 调节化合物,并确定 RIZ1 调节化合物调节 PR 活性的能力。进一步提供了一种方法,用于鉴定
雌激素受体阳性(ER+)肿瘤患者对内分泌治疗应答可能性降低的个体。该方法包括确定肿瘤的RIZ1状态,其中异常的RIZ1状态将个体鉴定为对内分泌治疗应答可能性降低的个体。